18. Nucleic Acid Vaccination
- W. John W. Morrow PhD, DSc, FRCPath3,
- Nadeem A. Sheikh PhD4,
- Clint S. Schmidt PhD5,
- D. Huw Davies PhD6
Published Online: 20 JUN 2012
DOI: 10.1002/9781118345313.ch18
Copyright © 2012 Blackwell Publishing Ltd
Book Title
Vaccinology: Principles and Practice
Additional Information
How to Cite
Wahren, B. and Liu, M. A. (2012) Nucleic Acid Vaccination, in Vaccinology: Principles and Practice (eds W. J. W. Morrow, N. A. Sheikh, C. S. Schmidt and D. H. Davies), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781118345313.ch18
Editor Information
- 3
Seattle, WA, USA
- 4
Dendreon Corporation, Seattle, WA, USA
- 5
NovaDigm Therapeutics, Inc., Grand Forks, ND, USA
- 6
University of California at Irvine, Irvine, CA, USA
Publication History
- Published Online: 20 JUN 2012
- Published Print: 3 AUG 2012
ISBN Information
Print ISBN: 9781405185745
Online ISBN: 9781118345313
- Summary
- Chapter
- References
Keywords:
- nucleic acids;
- DNA vaccines;
- immunotherapeutics;
- infectious diseases
Summary
DNA vaccines can generate the type of immunity needed for protection against a variety of diseases, either via the induction of cross-strain cellular immune responses, or high levels of cellular immunity, and often humoral immunity. Modifications of DNA sequences are easily made and confer new properties, such as exposing desirable neutralizing antigens or adding cytokine-inducing properties. But the most compelling rationale for DNA vaccines is to offer the potential for making vaccines and therapeutics directed against diseases that to date have not been effectively addressed by earlier technologies, including chronic infections, cancers, and diseases due to genetic aberrations. The DNA technology may thus serve not only to deliver new vaccines but also as new immunotherapeutics in chronic diseases where additional long-term delivery of an endogenous substance is required.